Welcome to the e-CCO Library!

P687: Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study
Year: 2022
Source: ECCO'22
Authors: Loveikyte, R.(1,2);Boer, M.(1);van der Meulen, C.N.(1);ter Steege, R.W.F.(3);Tack, G.(4);Kuyvenhoven, J.(5);Jharap, B.(6);Vu, M.K.(7);Vogelaar, L.(8);West, R.L.(9);van der Marel, S.(10);Römkens, T.(11);Mujagic, Z.(12);Hoentjen, F.(13,14);van Bodegraven, A.A.(15);van Schaik, F.D.M.(16);de Vries, A.C.(17);Dijkstra, G.(2);van der Meulen-de Jong, A.E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P688 Effect of golimumab induction therapy on histologic disease profile in patients with moderate to severe ulcerative colitis: Results from the randomised, placebo-controlled Phase 3 PURSUIT-SC trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Johansson1, C. Weinstein2, A. MEEHAN3, A. Tzontcheva4, P. Xu4, C. Marano5, G. de Hertogh6

Created: Thursday, 30 January 2020, 10:12 AM
P688: Association of Akkermansia muciniphila with a healthy gut microbiome
Year: 2021
Source: ECCO'21 Virtual
Authors: Ellul, S.(1);Rausch , P.(2);PIsani, A.(3);Bang, C.(4);Ellul, P.(3);Franke, A.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P688: Crohn's disease patients with a concordant family history are diagnosed earlier and are at increased risk for complicated disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Borren N.*1,2, Conway G.1, Garber J.1,3, Khalili H.1,3, Yajnik V.1,3, Xavier R.1,3, Ananthakrishnan A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P688: Demographic, clinical, and therapeutic characteristics of a cohort of 238 patients with ulcerative colitis from two medical centres from Uruguay
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.J. Luciano1, A. Noria2, B. Iade1,3*

Created: Thursday, 21 February 2019, 9:14 AM
P688: Patient preferences in medication to treat Ulcerative Colitis: a discrete choice experiment
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Straatmijer, T.(1)*;van den Akker-van Marle, E.(2);van der Horst, D.(3);Scherpenzeel, M.(3);Duijvestein, M.(4);van der Meulen, A.(5);
Created: Friday, 14 July 2023, 11:12 AM
P688: Sex difference in inflammatory bowel disease patients regarding depression: a nationwide population based study in Korea
Year: 2022
Source: ECCO'22
Authors: Moon, J.M.(1);Han, K.(2);Shin, S.Y.(1);Choi, C.H.(1);Kim, J.S.(3);
Created: Friday, 11 February 2022, 3:56 PM
P688: Ustekinumab in resistant Crohn’s disease: 1-year UK IBD tertiary referral centre ‘real-world’ experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. P. Borg-Bartolo*1, K. Kemp1, R. P. Willert1, A. J. Makin1, S. E. Levison1

Created: Friday, 22 February 2019, 9:41 AM
P689 Patient-reported outcomes (PRO-2) and intestinal ultrasound in ulcerative colitis patients: subanalysis of the TRUST&UC study cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Maaser1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, T. Kucharzik5

Created: Thursday, 30 January 2020, 10:12 AM
P689: Aeromonas infection and Inflammatory Bowel Disease: a single tertiary center analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Alves Da Silva, J.(1);Pereira Guedes, T.(1);Falcão, D.(1);Neves, S.(2);Costa, P.(3);Lago, P.(1);Pedroto, I.(1);Salgado, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P689: Biologics utilization in children with inflammatory bowel diseases is higher and earlier than in adults: a report from the epi-IIRN group
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Friedman M.*1, Axelrod R.1,2, Rosenblum J.3, Zigman N.3, Goren I.3, Lederman N.4, Cohen N.4, Matz E.5, Dushnitzky D.5, Borovsky N.5, Gavish M.2, Focht G.1, Avitzour M.1, Dotan I.6, Benchimol E.7, Turner D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P689: Multicenter, cross-sectional, observational study on Epstein–Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan
Year: 2022
Source: ECCO'22
Authors: Miura, M.(1);Shimizu, H.(2);Saito, D.(1);Miyoshi, J.(1);Matsuura, M.(1);Kudo, T.(3);Hirayama, D.(4);Yoshida, M.(5);Arai, K.(2);Iwama, I.(5);Nakase, H.(4);Shimizu, T.(3);Hisamatsu, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P689: Predictive transcriptional signatures associated to vedolizumab therapy response in patients with ulcerative colitis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Camba Gómez, M.(1)*;Arosa , L.(1);Calviño-Suárez, C.(2);Bastón-Rey, I.(2);Ferreiro-Iglesias, R.(2);Porto, M.(2);Nieto, L.(2);Domínguez-Muñoz, J.E.(2);Barreiro-de Acosta, M.(2);Conde-Aranda, J.(1);
Created: Friday, 14 July 2023, 11:12 AM
P689: The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Lev-Tzion*1, T. Ben-Moshe1, G. Abitbol1, O. Ledder1,2, A. Levine3,4, S. Peleg5,6, P. Millman7, R. Shaoul6,8, H. Shamaly9, A. On10,11, M. Kori2,12, A. Assa13,14, S. Cohen4,15, E. Broide4,16, D. Turner1,2

Created: Friday, 22 February 2019, 9:41 AM
P689: UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Gordon1*, R. Gadhok1, A. Ibarra1,2, J.O. Lindsay1,3

Created: Thursday, 21 February 2019, 9:14 AM
P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.S. Macaluso1, M. Ventimiglia1, W. Fries2, A. Viola2, M. Cappello3, B. Scrivo3, A. Magnano4, D. Pluchino4, S. Camilleri5, S. Garufi5, R. Di Mitri6, F. Mocciaro6, G. Magrì7, C. Ferracane7, M. Citrano8, F. Graziano8, C. Bertolami9, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Created: Thursday, 30 January 2020, 10:12 AM
P690: Ambient air quality does not affect disease course in inflammatory bowel disease – a population based risk factor analysis using geographic information systems
Year: 2017
Source: ECCO '17 Barcelona
Authors:

van den Heuvel T.*1, Bijnens E.2, Verhaegh B.1,3, Nawrot T.2, Zeegers M.4,5, Masclee A.1,3, Oostenbrug L.6, Romberg-Camps M.6, Jonkers D.1, Pierik M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P690: Changes of intestinal microbiota in patients with inflammatory bowel diseases
Year: 2021
Source: ECCO'21 Virtual
Authors: Baryshnikova, N.(1);Uspenskiy, Y.(1);Suvorova, M.(2);Lyudyno , V.(2);Suvorov, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P690: Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Berends1,2*, A. Strik2, J. Jansen3, N. de Boer4, J. Brandse4, G. D'Haens2, R. Mathôt1, M. Löwenberg2

Created: Thursday, 21 February 2019, 9:14 AM
P690: Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Favale1, S. Onali*1, F. Caprioli2, D. Pugliese3, A. Armuzzi3, F. S. Macaluso4, A. Orlando4, A. Viola5, W. Fries5, G. Mocci6, F. Chicco7, P. Usai7, A. Rispo8, F. Castiglione8, E. Calabrese1, L. Biancone1, G. Monteleone1, M. C. Fantini1

Created: Friday, 22 February 2019, 9:41 AM